drugset

drugset / Trial / NCT03609359

Lenvatinib and Pembrolizumab Simultaneous Combination Study

NCT03609359 ↗

Phase 2 Completed 29 enrolled National Cancer Center Hospital East Eisai Inc. · collab Merck Sharp & Dohme LLC · collab

NaSingle-groupOpen-labelTreatment

Summary

The efficacy and safety of the use of pembrolizumab in combination with lenvatinib.

Timeline

Start: 2018-10-03
Primary completion: 2021-04-30
Completion: 2021-04-30

Publications

Kawazoe A, Fukuoka S, Nakamura Y, Kuboki Y, Wakabayashi M, Nomura S, Mikamoto Y, Shima H, Fujishiro N, Higuchi T, Sato A, Kuwata T, Shitara K. Lenvatinib plus pembrolizumab in patients with advanced gastric cancer in the first-line or second-line setting (EPOC1706): an open-label, single-arm, phase 2 trial. Lancet Oncol. 2020 Aug;21(8):1057-1065. doi: 10.1016/S1470-2045(20)30271-0. Epub 2020 Jun 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Lenvatinib	Small molecule	20 mg	Oral
Subject	Pembrolizumab	Monoclonal antibody	200 mg	Intravenous

Indications